top of page
Cardiotoxicology remains a serious side effect in response to certain treatments as well as a major cause of clinical trial drug failures. iPSC-derived cardiomyocytes (CM) are powerful tool for studying the response of the human heart to different compounds in advance of clinical trials. Using human iPSC-CM, StemoniX creates functional cardiomyocyte spheroids to study the impact compounds have on the electrophysiology and structure of cardiomyocytes.
Testing strategies include acute and chronic exposure with single or repeated dosing strategies as well as molecular, structural, cell health/viability, and functional endpoints to provide a holistic picture of compound impact on cardiac function.
bottom of page